Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT (S15.002)

To evaluate the long-term safety and efficacy of zilucoplan, a macrocyclic peptide complement component 5 inhibitor, up to 96 weeks in patients with acetylcholine receptor autoantibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) in an interim analysis of RAISE-XT (NCT04225871).